Current strategies for the inhibition of hepatic glucose production in type 2 diabetes
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Diabetes is a complex disease involving multiple organs with dysregulation in glucose and lipid metabolism. Hepatic insulin insensitivity can contribute to elevated fasting glucose levels and impaired glucose tolerance in individuals with diabetes. Several currently available therapeutics address defects at the liver. Metformin inhibits glucose production, potentially through effects on AMPK. Thiazolidinediones activate PPAR-gamma and improve hepatic insulin sensitivity, primarily through indirect effects on lipid metabolism. Insulin analogs and secretagogues suppress glucose production and increase liver glucose utilization by both direct and indirect hepatic actions. Incretins, incretin mimetics, and dipeptidyl peptidase-4 inhibitors reduce postprandial hepatic glucose production by increasing insulin secretion and limiting glucagon release, as well as through possible direct effects on the liver. Pramlintide reduces the increase in plasma glucagon that occurs following a meal in individuals with diabetes, and may thereby suppress inappropriate stimulation of liver glucose production. Many other hepatic targets are being considered which may lead to alternative strategies for the treatment of diabetes. This review focuses on currently available therapeutics which target insulin resistance in the liver.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 2×
“Glucagon-like peptide-1 (GLP-1) is a gut derived incretin peptide which is released following the ingestion of food, stimulating insulin secretion in a glucose dependent manner (91).”
BackgroundCritical nodes in signalling pathways: insights into insulin action
Taniguchi, C. M., Emanuelli, B., & Kahn, C. R. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1837 · Cited by 2,760 · cited 1×
“The direct effect results from the interaction of the hormone with its hepatic receptor and involves the classic Akt signaling cascade (81).”
BackgroundNuclear Receptors and Lipid Physiology: Opening the X-Files
Chawla, A., Repa, J. J., Evans, R. M., & Mangelsdorf, D. J. (2001) · Science · doi:10.1126/science.294.5548.1866 · Cited by 2,085
Mechanism of free fatty acid-induced insulin resistance in humans.
Roden, M., Price, T. B., Perseghin, G., Petersen, K. F., Rothman, D. L., Cline, G. W., & Shulman, G. I. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118742 · Cited by 1,539 · cited 1×
“Obesity associated increases in circulating FFAs and hepatic TG storage correlate with reduced insulin mediated glucose uptake and production at the liver (34, 44, 45).”
BackgroundSchoonjans, K., Peinado‐Onsurbe, J., Lefebvre, A. M., Heyman, R. A., Briggs, M., Deeb, S., Staels, B., & Auwerx, J. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00918.x · Cited by 1,173
Pajvani, U. B., Hawkins, M., Combs, T. P., Rajala, M. W., Doebber, T., Berger, J. P., Wagner, J. A., Wu, M., Knopps, A., Xiang, A. H., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311113200 · Cited by 1,163
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus
Stumvoll, M., Nurjhan, N., Perriello, G., Dailey, G., & Gerich, J. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330903 · Cited by 1,148 · cited 1×
“(9) used the [(14)C]lactate approach in an earlier study and concluded that an alteration in gluconeogenesis explains metformin’s effect, while Christiansen et al.”
MethodMechanism by which metformin reduces glucose production in type 2 diabetes.
Hundal, R. S., Krssak, M., Dufour, S., Laurent, D., Lebon, V, Chandramouli, V, Inzucchi, S. E., Schumann, W. C., Petersen, K. F., Landau, B. R., et al. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2063 · Cited by 1,052 · cited 2×
“(8), seven T2D subjects and seven control subjects were assessed before and after treatment with metformin (TID; total dose ~ 2.”
BackgroundMethodHypothalamic insulin signaling is required for inhibition of glucose production
Obici, S., Zhang, B. B., Karkanias, G., & Rossetti, L. (2002) · Nature Medicine · doi:10.1038/nm1202-798 · Cited by 904 · cited 1×
“More recently, it has been demonstrated in rodents that insulin can reduce glucose output by the liver through an action in the hypothalamus (88).”
BackgroundStudies of pancreatic alpha cell function in normal and diabetic subjects
Unger, R. H., Aguilar-Parada, E., Müller, W. A., & Eisentraut, A. M. (1970) · Journal of Clinical Investigation · doi:10.1172/jci106297 · Cited by 837 · cited 2×
“Glucagon is inappropriately elevated following a meal in T2D patients (105-107) and is therefore considered a component of liver insulin resistance.”
BackgroundEfficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus
Inzucchi, S. E., Maggs, D. G., Spollett, G. R., Page, S. L., Rife, F. S., Walton, V., & Shulman, G. I. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381303 · Cited by 794 · cited 1×
“Greater suppression of glucose production with TZD treatment was also observed at low (42) but not higher (42, 67, 68) insulin clamp levels after longer periods of treatment (8 to 16 weeks).”
BackgroundMiyazaki, Y., Mahankali, A., Matsuda, M., Mahankali, S., Hardies, J., Cusi, K., Mandarino, L. J., & DeFronzo, R. A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.6.8567 · Cited by 726
Mayerson, A. B., Hundal, R. S., Dufour, S., Lebon, V., Befroy, D., Cline, G. W., Enocksson, S., Inzucchi, S. E., Shulman, G. I., & Petersen, K. F. (2002) · Diabetes · doi:10.2337/diabetes.51.3.797 · Cited by 647
Gastaldelli, A., Cusi, K., Pettiti, M., Hardies, J., Miyazaki, Y., Berria, R., Buzzigoli, E., Sironi, A. M., Cersosimo, E., Ferrannini, E., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.068 · Cited by 629 · cited 1×
“Visceral adiposity is associated with hepatic insulin resistance in nondiabetic and T2D subjects (37, 38).”
BackgroundMitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone.
Wilson-Fritch, L., Nicoloro, S., Chouinard, M., Lazar, M. A., Chui, P. C., Leszyk, J., Straubhaar, J., Czech, M. P., & Corvera, S. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21752 · Cited by 616 · cited 1×
“Finally, FFA oxidation is increased through the induction of the coactivator PGC1a, which promotes mitochondrial biogenesis (53).”
BackgroundKorenblat, K. M., Fabbrini, E., Mohammed, B. S., & Klein, S. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.075 · Cited by 592 · cited 1×
“1172 was shown to be the best predictor of insulin action in liver, skeletal muscle and adipose tissue (46).”
BackgroundYoon, M. J., Lee, G. Y., Chung, J.-J., Ahn, Y. H., Hong, S. H., & Kim, J. B. (2006) · Diabetes · doi:10.2337/db05-1322 · Cited by 546 · cited 1×
“Treatment with adiponectin in vitro resulted in increased activity of acylCoA oxidase, carnitine palmitoyl transferase-1 and fatty acid binding protein, leading to increased fatty acid oxidation (71).”
BackgroundTiikkainen, M., Häkkinen, A.-M., Korsheninnikova, E., Nyman, T., Mäkimattila, S., & Yki-Järvinen, H. (2004) · Diabetes · doi:10.2337/diabetes.53.8.2169 · Cited by 524 · cited 2×
“(21) carried out four years earlier, four months of metformin treatment in previously untreated T2D patients was shown to be associated with an enhanced ability of insulin to inhibit glucose production.”
BackgroundKim, Y. D., Park, K.-G., Lee, Y.-S., Park, Y.-Y., Kim, D.-K., Nedumaran, B., Jang, W. G., Cho, W.-J., Ha, J., Lee, I.-K., et al. (2008) · Diabetes · doi:10.2337/db07-0381 · Cited by 422
Natali, A., & Ferrannini, E. (2006) · Diabetologia · doi:10.1007/s00125-006-0141-7 · Cited by 377
Dunning, B. E., & Gerich, J. E. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0026 · Cited by 369
Prigeon, R. L., Quddusi, S., Paty, B., & D'Alessio, D. A. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00024.2003 · Cited by 199
Splanchnic regulation of glucose production
Wahren, J., & Ekberg, K. (2007) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.27.061406.093806 · Cited by 185 · cited 1×
“In the post-absorptive state, reduced suppression of hepatic glucose production and abnormal liver glucose clearance contribute to impaired glucose tolerance and postprandial hyperglycemia (3).”
BackgroundNew hepatic targets for glycaemic control in diabetes
Agius, L. (2007) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2007.09.001 · Cited by 155
Sindelar, D. K., Balcom, J. H., Chu, C. A., Neal, D. W., & Cherrington, A. D. (1996) · Diabetes · doi:10.2337/diab.45.11.1594 · Cited by 134 · cited 1×
“1173 In a study carried out in the dog (89), there was a very similar fall in glucose production (60-75%) seen in response to a modest rise in plasma insulin (~14 μU/ml) brought about selectively at the liver (i.”
BackgroundFineman, M. S., Koda, J. E., Shen, L. Z., Strobel, S. A., Maggs, D. G., Weyer, C., & Kolterman, O. G. (2002) · Metabolism · doi:10.1053/meta.2002.32022 · Cited by 129
Mechanism of fat-induced hepatic gluconeogenesis: effect of metformin
Song, S., Andrikopoulos, S., Filippis, C., Thorburn, A. W., Khan, D., & Proietto, J. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.2.e275 · Cited by 122 · cited 2×
“A variety of hepatic gluconeogenic targets have been identified including glucose-6-phosphatase (G6Pase) (16), fructose-1,6-bisphosphatase (F16BPase) (17) and phosphoenolpyruvate carboxykinase (PEPCK) (14).”
BackgroundBasu, R., Shah, P., Basu, A., Norby, B., Dicke, B., Chandramouli, V., Cohen, O., Landau, B. R., & Rizza, R. A. (2008) · Diabetes · doi:10.2337/db07-0827 · Cited by 63
Insulin action on the liver in vivo
Cherrington, A. D., Moore, M. C., Sindelar, D. K., & Edgerton, D. S. (2007) · Biochemical Society Transactions · doi:10.1042/bst0351171 · Cited by 43 · cited 1×
“The indirect effects of insulin include an action on fat, muscle, the alpha cell and the brain (82, 83).”
Background
Cited by
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70704 · Cited by 795
FoxO integration of insulin signaling with glucose and lipid metabolism
Lee, S., & Dong, H. H. (2017) · Journal of Endocrinology · doi:10.1530/joe-17-0002 · Cited by 360
Foxo1 integrates insulin signaling with mitochondrial function in the liver
Cheng, Z., Guo, S., Copps, K., Dong, X., Kollipara, R., Rodgers, J. T., Depinho, R. A., Puigserver, P., & White, M. F. (2009) · Nature Medicine · doi:10.1038/nm.2049 · Cited by 321
Hepato-Incretin Function of GLP-1: Novel Concept and Target in Type 1 Diabetes
Ahrén, B. (2015) · Diabetes · doi:10.2337/db14-1671 · Cited by 13
“This would allow the use of submaximal doses of the two strategies, resulting in maximal hepatic glucose production and avoidance of adverse events (3).”
BackgroundMethod
Metadata
- Authors
- Edgerton, D.
- Venue
- Frontiers in Bioscience
- Publisher
- IMR Press
- Published
- 2009
- Volume
- Volume
- Issue
- 14
- Pages
- 1169
- ISSN
- 1093-4715 (ISSN-L)
- 1093-9946
- DOI
- 10.2741/3301
- OpenAlex
- W1594680408
- Cited by
- 54
- References
- 30
- FWCI
- 4.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.